Artivion Inc. (AORT) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

Per the Roarable RQD rating, AORT scores 41 out of 100 with a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are: Fundamental Cash Engine at 5/20 (ROIC 4.5%; FCF yield 0.07%); Whale 13F Flow at 6/20 (institutional accumulation and options positioning); Insider Conviction at 8/20 (SEC Form 4 and Congressional PTR cluster flow); Macro Regime Fit at 9/20 (Beta 1.0; sector sensitivity); and Forensic Balance Sheet at 13/20 (Altman Z 2.46; Piotroski F 9/9; Debt/Equity 0.48). The strongest pillar is the forensic balance sheet, which indicates the company's structural solvency and accounting quality screen well. The weakest pillar is the fundamental cash engine, where a 0.07% FCF yield against a $1.14B market cap means very little free cash is being generated relative to the equity valuation. For a prospective investor, the upside case rests on the balance sheet holding up and on operating cash flow improving; the valuation tradeoff is that the stock carries a trailing P/E of 117 against EPS of 0.2, so the price already embeds substantial expectations. Flow pillars are middling to weak, meaning the ownership and insider signals do not offer strong confirmation. Taken together, the rating frames AORT as a name where solvency is not the primary concern but earnings power and cash conversion are unproven at current prices.

Artivion Inc. (AORT) is a NYSE-listed issuer in the Health Care sector, Medical/Dental Instruments industry, per the profile section. Not available in source data for product lines, customer base, or revenue model detail beyond the segment classification. Gross margin is 64.4%, operating margin 7.6%, and net margin 2.2%, per the market data section.

Per the SEC financials, revenue grew from $354.0M in FY 2023 to $441.3M in FY 2025, and net income moved from $-30.7M to $9.8M over the same span. Operating margin is 7.6% and net margin 2.2% per the market data section. ROIC is 4.5%. Per the Roarable RQD rating, the Altman Z-Score is 2.46 and the Piotroski F-Score is 9/9. Debt declined from $314.2M in FY 2024 to $215.1M in FY 2025 while cash rose to $64.9M, and the Debt/Equity ratio is 0.48 per the RQD forensic pillar. FCF fell from $11.0M in FY 2024 to $0.8M in FY 2025.

The news wire contains six items, all tagged YELLOW with impact label MARKET WIRE, from sources including Yahoo Finance Singapore, Yahoo Finance, TradingView, StockStory, Simply Wall St, and Stock Titan. Headlines reference a cash-flow-based valuation view ("May Be 13% Undervalued On Cash Flow"), a "Cautious Full Year Outlook" discussed by Simply Wall St, a Q2 peer comparison in medical devices, and a BlackRock stake update noting an iShares ETF interest above 5%. Risk watch items include the cautious outlook headline and the low FCF yield noted in the RQD cash engine pillar. Per the Butterfly Supply-Chain Graph, the sector is Health Care, the industry is Medical/Dental Instruments, the supply chain is listed as NONE, and no butterfly links or proprietary signals are recorded. Specific catalyst dates and event details beyond the headlines are not available in source data.

• What are the company's specific product lines and customer concentration, since the source data only provides sector classification?
• Why is FCF down from $11.0M in FY 2024 to $0.8M in FY 2025 despite revenue growth, and what drove the change in cash conversion?
• What does the "cautious full year outlook" headline specifically guide to, and is it reflected in forward estimates?
• What is the analyst consensus rating and price target, given that analyst data is absent?
• Who are the institutional and insider holders behind the whale and insider pillar scores, since holder data is absent?